Latest Benitec Biopharma Limited Stories
SYDNEY, March 11, 2015 /PRNewswire/ -- Benitec Biopharma (ASX: BLT; OTCPK: BTEBY), a biopharmaceutical company focused on providing potentially curative therapies with its proprietary gene-silencing
- Two research groups report importance of beta III-tubulin in pancreatic and kidney cancer SYDNEY, Jan.
SYDNEY, May 30, 2014 /PRNewswire/ -- Benitec Biopharma Limited (ASX: BLT) (OTC: BTEBY) is pleased to announce the establishment of a sponsored, Level 1 American Depositary Receipt (ADR) program
SYDNEY, May 29, 2014 /PRNewswire/ -- RNAi-based therapeutics company, Benitec Biopharma Limited (ASX: BLT) is pleased to announce that it has dosed the first patient in its 'first in man', Phase I/IIa
Shareholders Overwhelmingly Approve Second AUD $15.7 million Tranche Following General Meeting SYDNEY, April 15, 2014 /PRNewswire/ -- Benitec Biopharma Limited (ASX: BLT), today announced
Company to Receive up to approximately AUD $31.5 million to Accelerate Clinical Development TT-034 for Treating Hepatitis C SYDNEY, Feb.
- A young chicken: also used as a pet name for children.